The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.
Novel non-peptidic neuropeptide Y Y 2 receptor antagonists
作者:Jill A. Jablonowski、Wenying Chai、Xiaobing Li、Dale A. Rudolph、William V. Murray、Mark A. Youngman、Scott L. Dax、Diane Nepomuceno、Pascal Bonaventure、Timothy W. Lovenberg、Nicholas I. Carruthers
DOI:10.1016/j.bmcl.2003.12.057
日期:2004.3
Through SAR studies of a piperidinylindoline cinnamide HTS lead, the first potent, non-peptide, low molecular weight selective Neuropeptide Y Y-2 (NPY Y-2) antagonists have been synthesized. The SAR studies around the piperidinyl, the indolinyl, and the cinnamyl moieties are discussed. (C) 2003 Elsevier Ltd. All rights reserved.
US7317025B2
申请人:——
公开号:US7317025B2
公开(公告)日:2008-01-08
Non-peptidic NPY Y2 receptor inhibitors
申请人:Carruthers I. Nicholas
公开号:US20050070534A1
公开(公告)日:2005-03-31
The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.